Hospital Ruber Juan Bravo
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Researchers at Hospital Ruber Juan Bravo are evaluating a novel oral factor XIa inhibitor to lower the chance of another clot‑related event in patients who have experienced an acute ischemic stroke or a high‑risk transient ischemic attack. The study also tracks safety by monitoring major bleeding incidents.
- Evaluation of a new oral antithrombotic agent
- Assessment of bleeding risk alongside standard therapy
- Long‑term prevention of recurrent stroke
The trial involves 11 investigators and reflects the department’s commitment to advancing cardiovascular care in Madrid, Europe.
Neoplasms
The neurology department is conducting a study on an innovative antibody‑drug conjugate for men with metastatic castration‑resistant prostate cancer. The objective is to determine whether the therapy can extend progression‑free survival as measured by radiographic imaging.
- Targeted antibody‑drug conjugate for advanced prostate cancer
- Imaging‑based evaluation of tumor control
- Investigation of optimal dosing levels
With a team of 11 investigators, the site contributes to cutting‑edge oncology research within the Spanish healthcare system.
Nervous System Diseases
A clinical investigation at the hospital tests the effectiveness of a botulinum toxin formulation (Dysport®) in reducing the number of episodic migraine days for adults suffering frequent attacks. Participants receive injections and are compared to a placebo to assess symptom improvement.
- Botulinum toxin injections for migraine prevention
- Reduction of monthly migraine days
- Safety and tolerability compared with placebo
The study, supported by 11 investigators, highlights the department’s focus on improving quality of life for patients with neurological disorders in Madrid.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 53 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 51 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Ruber Juan Bravo
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 53 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 3 | Unknown | 2025-10-29 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.